These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28862945)

  • 21. Risk Factor Control in Stroke Survivors with Diagnosed and Undiagnosed Diabetes: A Ghanaian Registry Analysis.
    Sarfo FS; Akassi J; Agyei M; Kontoh S; Ovbiagele B
    J Stroke Cerebrovasc Dis; 2020 Dec; 29(12):105304. PubMed ID: 32992189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of achievement of A1c, blood pressure, and cholesterol (ABC) goal in veterans with diabetes.
    Vouri SM; Shaw RF; Waterbury NV; Egge JA; Alexander B
    J Manag Care Pharm; 2011 May; 17(4):304-12. PubMed ID: 21534641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy.
    Figliuzzi I; Presta V; Citoni B; Miceli F; Simonelli F; Battistoni A; Coluccia R; Ferrucci A; Volpe M; Tocci G
    Clin Cardiol; 2018 Jun; 41(6):788-796. PubMed ID: 29604091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study.
    Ting RZ; Yang X; Yu LW; Luk AO; Kong AP; Tong PC; So WY; Chan JC; Ma RC
    Cardiovasc Diabetol; 2010 Nov; 9():77. PubMed ID: 21092182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multifactorial control and treatment intensity of type-2 diabetes in primary care settings in Catalonia.
    Mengual L; Roura P; Serra M; Montasell M; Prieto G; Bonet S
    Cardiovasc Diabetol; 2010 Mar; 9():14. PubMed ID: 20350315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary.
    Mark L; Vallejo-Vaz AJ; Reiber I; Paragh G; Kondapally Seshasai SR; Ray KK
    Atherosclerosis; 2015 Jul; 241(1):62-8. PubMed ID: 25966441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study.
    Wong ND; Zhao Y; Patel R; Patao C; Malik S; Bertoni AG; Correa A; Folsom AR; Kachroo S; Mukherjee J; Taylor H; Selvin E
    Diabetes Care; 2016 May; 39(5):668-76. PubMed ID: 27208374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices.
    Corcillo A; Pivin E; Lalubin F; Pitteloud N; Burnier M; Zanchi A
    Swiss Med Wkly; 2017; 147():w14459. PubMed ID: 28695552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in body mass index, glycosylated hemoglobin A1C, blood pressure, and LDL-cholesterol among type 2 diabetes patients in Malaysia: A population-based longitudinal study.
    Wan KS; Moy FM; Mustapha FI; Ismail M; Hairi NN
    J Diabetes; 2021 Nov; 13(11):915-929. PubMed ID: 34142456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
    Brinton EA; Ballantyne CM; Bays HE; Kastelein JJ; Braeckman RA; Soni PN
    Cardiovasc Diabetol; 2013 Jul; 12():100. PubMed ID: 23835245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway.
    Cook S; Hopstock LA; Eggen AE; Bates K; Iakunchykova O; Kontsevaya A; McKee M; Schirmer H; Voevoda M; Kudryavtsev AV; Malyutina S; Leon DA
    BMC Cardiovasc Disord; 2020 May; 20(1):234. PubMed ID: 32430002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study.
    Mwita JC; Francis JM; Omech B; Botsile E; Oyewo A; Mokgwathi M; Molefe-Baikai OJ; Godman B; Tshikuka JG
    BMJ Open; 2019 Jul; 9(7):e026807. PubMed ID: 31340960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance of Clinical Endpoints After Discharge from a Pharmacist-Managed Risk Reduction Clinic at a Veterans Affairs Medical Center.
    Sherrill CH; Pentecost A; Wood EE
    J Manag Care Spec Pharm; 2016 Jan; 22(1):14-20. PubMed ID: 27015047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register.
    Eeg-Olofsson K; Zethelius B; Gudbjörnsdottir S; Eliasson B; Svensson AM; Cederholm J
    Diab Vasc Dis Res; 2016 Jul; 13(4):268-77. PubMed ID: 27190080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective, cross-sectional study of real-world values of cardiovascular risk factors using a healthcare database in Japan.
    Shima D; Ii Y; Yamamoto Y; Nagayasu S; Ikeda Y; Fujimoto Y
    BMC Cardiovasc Disord; 2014 Sep; 14():120. PubMed ID: 25231128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.